Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare News In Brief

This article was originally published in The Gray Sheet

Executive Summary

New-tech intraocular lens: CMS is considering whether Rayner Surgical's C-flex Model 570C intraocular lens meets the criteria for a new class of new-technology IOLs. The designation would provide a $50 payment bonus for lenses implanted for cataracts in ambulatory surgical centers for five years. Rayner Surgical says its product, which was approved by FDA in May 2007, reduces silicone oil adhesion and oil-induced opacification associated with vitreoretinal surgery. CMS questions whether the benefit is clinically demonstrable compared with other IOLs. Under current new-tech IOL classifications, four lenses are eligible for a bonus payment through February 2011 based on their ability to reduce spherical aberrations: Advanced Medical Optics' Tecnis, Alcon's Acrysof IQ, Bausch & Lomb's Sofport AO and STAAR's Affinity Collamer (1"The Gray Sheet" March 19, 2007, In Brief)

Related Content

Ambulatory Surgical Center Payment Reform Enacted; Facilities Bitter
B&L lens payment bonus



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts